
Professor @hopkinsmedicine | Director of #EndocrineHospitalists | Chief of #Endocrinology @SuburbanHosp | Endocrinology Expert Witness | Diabetes Expert Witness
Bethesda, MD
Joined May 2019
- Tweets355
- Following1.4K
- Followers1.8K
- Likes522
Mihail "Misha" Zilbermint, MD, MBA retweeted
.@HopkinsMedicine endocrinologist @zilbermint details the most common misconceptions people have about about GLP-1 drugs like Ozempic, Wegovy and Zepbound. @CBSNews
cbsnews.com/texas/news/what-…
Mihail "Misha" Zilbermint, MD, MBA retweeted
💡 Tips for initiating #CGM prior to hospital discharge, according to @zilbermint at @hopkinsmedicine
📌 Train hospital nurses on how to use #diabetes technology
📌 Be inclusive while also respecting a patient’s interest in using a CGM
@GoHealio
healio.com/news/endocrinolog…
Mihail "Misha" Zilbermint, MD, MBA retweeted
New @HopkinsMedicine protocol shows how hospitals can safely start continuous glucose monitoring (#CGM) at discharge—improving patient education & outcomes. @SageJournals journals.sagepub.com/doi/10.….
Mihail "Misha" Zilbermint, MD, MBA retweeted
🏥Starting a CGM during hospitalization could offer several benefits for patients with #diabetes.
@GoHealio spoke with @zilbermint about how hospitals can train staff and set up a plan to initiate CGM for patients as they are preparing to discharge.
healio.com/news/endocrinolog…
It is thrilling to see the new oral #obesity #GLP-1 drugs making their way into the U.S. market. A key question remains: what will the #cost be, and how will accessibility be addressed? cnbc.com/2025/08/24/eli-lill…
Mihail "Misha" Zilbermint, MD, MBA retweeted
Check out @TheEndoSociety's 2023 Clinical Practitioner Laureate Award recipient @zilbermint discussing @EliLillyandCo's new #obesity pill:
cnbc.com/2025/08/07/eli-lill…
Mihail "Misha" Zilbermint, MD, MBA retweeted
.@HopkinsMedicine endocrinologist @zilbermint discusses how Eli Lilly's obesity pill could be a game changer for patients. @CNBC
cnbc.com/2025/08/07/eli-lill…
Mihail "Misha" Zilbermint, MD, MBA retweeted
📱 MARD values between CGM and other #glucose measurement methods are not associated with laboratory values or vital signs, which provides “reassurance regarding the use of CGMs in the hospital setting."
@MayoClinic @zilbermint
healio.com/news/endocrinolog…
Mihail "Misha" Zilbermint, MD, MBA retweeted
“We need to treat prediabetes as an actual diagnosis — not just a warning sign.” says @HopkinsMedicine endocrinologist @zilbermint.
From Screening to Intervention: Optimizing Prediabetes Care in Primary Care Settings. @Medscape
wb.md/3Sqpk2Q
Mihail "Misha" Zilbermint, MD, MBA retweeted
📣 "CGMs brought from home demonstrated strong accuracy across a diverse hospitalized population, with more than 98% of values in clinically acceptable error grid zones."
@MayoClinic @zilbermint #diabetes #glucose
healio.com/news/endocrinolog…
What a wonderful collaboration! Thanks to @TheAACE for the invitation to join the effort!
New Guidelines on Lipids! American Association of Clinical Endocrinology Clinical Practice Guideline on Pharmacologic Management of Adults With Dyslipidemia @TheAACE #EndocrinePractice #EndoTwitter #LabmedTwitter endocrinepractice.org/articl…
Mihail "Misha" Zilbermint, MD, MBA retweeted
A summary of the updated @AmDiabetesAssn consensus report on hyperglycemic crisis management, which has been endorsed jointly by AACE, @EASDnews, @JBDSIP, @DiabetesTechSoc. Read more: endocrinepractice.org/articl… @Els_ENDO @vtangpricha #endocrinology
Mihail "Misha" Zilbermint, MD, MBA retweeted
A summary of the updated @AmDiabetesAssn consensus report on hyperglycemic crisis management, which has been endorsed jointly by AACE, @EASDnews, @JBDSIP, @DiabetesTechSoc. Read more: endocrinepractice.org/articl… @Els_ENDO @vtangpricha #endocrinology
Just published a new case report in @TheAACE #ClinicalCaseReports! It highlights the successful use of hyperinsulinemic-euglycemic therapy for severe calcium channel blocker overdose. aaceclinicalcasereports.com/…
#CMS will hold hospitals accountable for not reporting poor #glycemic outcomes. Will this make our hospitals safer for people living with #diabetes? doi.org/10.1177/193229682412…
Mihail "Misha" Zilbermint, MD, MBA retweeted
Excited to share the publication of our new book chapter new insights/ insulin and non-insulin approaches based on most recent guidelines.
Inpatient management of type 2 diabetes. Special thanks to @zilbermint for this opportunity. @HMethodistMD @MethodistHosp @AshRasool20
Mihail "Misha" Zilbermint, MD, MBA retweeted
Q&A: New guidance for monitoring pre-symptomatic type 1 diabetes healio.com/news/endocrinolog… @BreakthroughT1D @TheAACE @DiabetesCareADA @ADA_Pubs @HofNorthwellDOM @YTobiHarris
Mihail "Misha" Zilbermint, MD, MBA retweeted
New commentary on the ADA guidelines on DKA #EndocrinePractice by Drs Swapnil Khare, Garg, Shah and @zilbermint Navigating the New Frontiers of Hyperglycemic Crisis Management: Unveiling the Latest American Diabetes Association Consensus Report endocrinepractice.org/articl…
🚀 Exciting News! Our #EndocrineHospitalist team just published "Inpatient #Diabetes Management" in @NYASciences! @HopkinsMedicine @HopkinsHowardC @sibleyonline @SuburbanHosp @EndoHopkins
doi.org/10.1111/nyas.15190
Great piece by @MiriamETucker from @Medscape about the timing of #insulin administration in the #hospital and hypoglycemia reduction.
medscape.com/viewarticle/shi…








